Clinical Trials Browser

Phase 2 × Not yet recruiting × Hydroxyurea × Clear all

NCT06930352 2026-03-13

Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy

Phase 2 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute